Your browser doesn't support javascript.
loading
Multiple myeloma: 18F-FDG-PET/CT and diagnostic imaging.
Mihailovic, Jasna; Goldsmith, Stanley J.
Afiliación
  • Mihailovic J; Department of Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia; Technical Faculty "Mihajlo Pupin" Zrenjanin, University of Novi Sad, Novi Sad, Serbia.
  • Goldsmith SJ; Division of Nuclear Medicine & Molecular Imaging, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY; Department of Radiology, Weill Cornell Medical College, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address: sjg2002@med.cornell.edu.
Semin Nucl Med ; 45(1): 16-31, 2015 Jan.
Article en En | MEDLINE | ID: mdl-25475376
Multiple myeloma (MM) is a relatively rare hematologic disorder characterized by proliferation of plasma cells, primarily involving the bone marrow. Extramedullary involvement also occurs with poor prognosis. Asymptomatic plasma cell disorders, monoclonal gammopathy of uncertain significance, and smoldering MM, which do not require therapy, should be distinguished from symptomatic MM, which requires treatment. MM may present with CRAB, elevated Calcium levels, Renal insufficiency, Anemia, and Bone lesions (including lytic lesions and osteopenia), as well as elevated levels of serum M protein or urine M protein or both. Nonsecretory myeloma in which serum and urine M proteins are absent occurs rarely, accounting for 1%-5% of patients with myeloma, but low levels of abnormal immunoglobulins are often present. Staging of patients with MM is done according to the Durie and Salmon criteria based on laboratory testing (determination of hemoglobin, serum calcium, and serum and urine M proteins) and conventional radiography. A variety of diagnostic imaging procedures have been employed to assess the extent of disease in MM and to evaluate the response to treatment as well as provide surveillance for the detection of recurrent disease. These include whole-body x-ray, which despite its limitations is regularly used to detect lytic bone lesions; CT radiography; MRI; and a variety of radionuclide imaging procedures, with (18)F-FDG-PET/CT emerging as the radionuclide procedure of choice. Recently, the Durie-Salmon criteria have been upgrade to the Durie-Salmon PLUS system, which includes (18)F-FDG-PET/CT and MRI of the spine and pelvis.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tomografía Computarizada por Rayos X / Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Semin Nucl Med Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tomografía Computarizada por Rayos X / Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Semin Nucl Med Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos